by TractManager | Mar 31, 2021 | News
The Food and Drug Administration (FDA) has issued the following safety alerts:Acellular Dermal Matrix (ADM) Products Used in Implant-Based Breast ReconstructionThe FDA is informing patients, caregivers, and health care providers that certain acellular dermal matrix...
by TractManager | Mar 31, 2021 | Emerging Technology Report
The Portable Neuromodulation Stimulator (PoNS) device is a portable neuromodulation stimulator for short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis for use by prescription only as an adjunct to a supervised therapeutic...
by TractManager | Mar 30, 2021 | Health Technology Assessment
Focus of the Report: This report focuses on Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).Technology Description: Aquablation therapy is a minimally invasive procedure that ablates overgrown...
by TractManager | Mar 29, 2021 | Molecular Test Assessment
Focus of the Report: This report examines the analytical validity, clinical validity, and clinical utility of the Cologuard stool DNA test for the qualitative detection of colorectal neoplasia–associated DNA markers and for the presence of occult hemoglobin in human...
by TractManager | Mar 29, 2021 | Emerging Technology Report
Abecma (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior lines of therapy,...
Recent Comments